Zevra Reports Third Quarter 2026 Financial Results and Corporate Update
Quarterly profitability improved, while nine-month net income declined to $65.850 million from $71.064 million.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Zevra Therapeutics (ZVRA) reported third-quarter 2026 net revenue of $37.8 million, up 45% from the same quarter in 2025. MIPLYFFA contributed $34.0 million. Net income reached $19.2 million, or $0.26 per diluted share, versus a $0.5 million loss a year earlier; earnings included $5.1 million in noncash warrant and contingent value rights adjustments. Cash, cash equivalents and investments totaled $270.9 million at September 30.
MIPLYFFA received 13 prescription enrollment forms during the quarter, bringing the launch total to 197. Zevra anticipates filing a supplemental approval application for infants younger than 24 months in Q1 2027. European re-examination of arimoclomol's marketing application remains pending. The Phase 3 celiprolol trial added six patients, reaching 72 enrolled and four confirmed events. Research and administrative expenses increased year over year.
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Hollow bars mark forward-looking points. How the balance works
Positive
- Moderate pointQ3 net revenue of $37.8 million increased 45% from Q3 2025.
- Moderate pointQ3 net income of $19.2 million reversed a $0.5 million loss in Q3 2025.
- Moderate pointQ3 operating income of $11.580 million increased from $4.143 million in Q3 2025.
- Moderate pointCash, cash equivalents and investments of $270.9 million supported Zevra's assessment that resources cover its strategic priorities.
- Moderate pointMIPLYFFA prescription enrollment forms reached 197 since launch, including 13 received in Q3 2026.
- Moderate point. Forward-looking: it has not happened yet and may not happen.Supplemental MIPLYFFA application anticipated in Q1 2027 for infants younger than 24 months.
7 minor points
- Minor pointQ3 diluted earnings of $0.26 per share compared with a $0.01 loss a year earlier.
- Minor pointQ3 interest expense was zero, compared with $2.051 million in Q3 2025.
- Minor pointCeliprolol Phase 3 enrollment reached 72 patients, with six enrolled in Q3 2026.
- Minor pointNine-month revenue of $113.639 million increased from $72.345 million in 2025.
- Minor pointNine-month product revenue costs fell to $5.216 million from $14.962 million, excluding intangible asset amortization.
- Minor pointNine-month administrative expenses fell to $56.472 million from $57.262 million in 2025.
- Minor pointNine-month operating income reached $80.503 million, versus a $72.258 million operating loss in 2025.
Negative
- Moderate pointEuropean arimoclomol application re-examination remains pending following Zevra's request.
- Moderate pointNine-month net income declined to $65.850 million from $71.064 million in 2025.
- Minor pointQ3 product revenue costs rose to $1.8 million from $1.2 million, excluding intangible asset amortization.
- Minor pointQ3 research and development expense rose to $4.9 million from $3.4 million in Q3 2025.
- Minor pointQ3 selling, general and administrative expense rose to $19.1 million from $16.9 million a year earlier.
5 minor points
- Minor pointNine-month diluted earnings fell to $1.03 per share from $1.16 in 2025.
- Minor pointNine-month research and development expense increased to $13.815 million from $10.123 million in 2025.
- Minor pointNine-month debt extinguishment loss was $2.756 million, versus none in 2025.
- Minor pointNine-month derivative liability loss was $7.216 million, versus none in 2025.
- Minor pointNine-month income tax expense increased to $11.467 million from $2.948 million in 2025.
News Explained
The Q3 release reports that, as of
Details
Market move: ZVRA +8.87% in the Nov 4 session. Q3 2026 earnings report
On Nov 4, the first trading day after this news, ZVRA closed 8.87% above the previous close. Argus tracked a peak move of +3.7% during that session. Our momentum scanner recorded 16 alerts for this stock that day. That session’s volume was 3.0x the stock’s average daily volume.
Data tracked by StockTitan Argus for the Nov 4 session.
Key Figures
- Net revenue
- $37.8 million
- Q3 2026
- MIPLYFFA net revenue
- $34.0 million
- Q3 2026
- Revenue increase
- 45%
- Total net revenue over Q3 2025
- Net income
- $19.2 million
- Q3 2026
- Cash, cash equivalents and investments
- $270.9 million
- As of September 30, 2026
- DiSCOVER enrollment
- 72 patients
- Celiprolol Phase 3 trial total enrollment
- Confirmed events
- 4
- Celiprolol Phase 3 DiSCOVER trial
- Anticipated sNDA filing
- Q1 2027
- MIPLYFFA for infants less than 24 months of age
Previous Earnings Reports
-
Q2 revenue rose 53%; net income was $8.8 million and cash totaled $260.2 million.
-
Q1 revenue rose 78%, and the company prepaid its term loan.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
supplemental new drug application regulatory
marketing authorisation application regulatory
expanded access program medical
contingent value rights financial
AI-generated analysis. How Rhea-AI works. Not financial advice.
Operational execution fueled strong cash position of
Company to host conference call and webcast TODAY, November 3, 2026, at 4:30 p.m. ET
BOSTON, Mass., Nov. 03, 2026 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on bringing life-changing therapeutics to people living with rare diseases, today reported its financial results for the third quarter ended September 30, 2026.
“In the third quarter, we made continued progress across our business, building on MIPLYFFA's commercial performance in the U.S. and advancing our pipeline in support of our mission to redefine what’s possible in bringing life-changing therapies to people living with rare disease,” said Neil F. McFarlane, Zevra's President and Chief Executive Officer. “We remain focused on reaching more people living with Niemann-Pick disease type C, advancing celiprolol for vascular Ehlers-Danlos syndrome, and pursuing European access to arimoclomol. Our strong financial position enables us to advance these priorities while continuing to make arimoclomol available to eligible patients through our global Expanded Access Program.”
MIPLYFFA® (arimoclomol) Highlights
- U.S.: Received 13 MIPLYFFA prescription enrollment forms for Niemann-Pick disease type C (NPC) during Q3 2026, bringing the total to 197 since product launch.
- EU: The Company requested a re-examination of its Marketing Authorisation Application for arimoclomol for the treatment of NPC and is awaiting the outcome of the process.
- Global Expanded Access Program (EAP): As of September 30, 2026, 134 patients were enrolled in the global EAP.
- Following the publication of its pediatric data in Molecular Genetics and Metabolism Reports, Zevra met with the U.S. Food and Drug Administration (FDA) to discuss a potential supplemental New Drug Application (sNDA) for MIPLYFFA in infants less than 24 months of age. Company anticipates filing sNDA in Q1 2027.
Pipeline and Innovation Highlights
- Enrolled six patients in the event-driven Phase 3 DiSCOVER trial of celiprolol for the treatment of Vascular Ehlers-Danlos Syndrome during Q3 2026, bringing the total number of enrolled patients to 72, with a total of four confirmed events. The Company recently engaged with the FDA for a Type C meeting to discuss a potential submission strategy for celiprolol.
Q3 2026 Financial Highlights
- Revenue, Net:
$37.8 million for Q3 2026, which includes$34.0 million of MIPLYFFA net revenue,$0.2 million of OLPRUVA net revenue, and$3.6 million in net reimbursements from our global EAP. This was an increase in total net revenue of$11.7 million compared to$26.1 million in Q3 2025.
- Cost of Product Revenue:
$1.8 million for Q3 2026, excluding non-cash intangible asset amortization. Cost of product revenue for Q3 2025 was$1.2 million , excluding non-cash intangible asset amortization.
- Operating Expenses:
$24.1 million for Q3 2026, which includes non-cash stock compensation expense of$2.7 million . Total operating expenses for Q3 2025 were$20.4 million .
-
- R&D expense was
$4.9 million for Q3 2026, which was an increase of$1.5 million compared to$3.4 million for Q3 2025, due primarily to our ongoing investment in arimoclomol efforts and in the celiprolol development program.
- R&D expense was
-
- SG&A expense was
$19.1 million for Q3 2026, which was an increase of$2.2 million compared to$16.9 million for Q3 2025, due primarily to commercial and infrastructure related costs.
- SG&A expense was
- Net income (loss): Net income of
$19.2 million , or$0.31 per basic and$0.26 diluted share for Q3 2026, compared to a net (loss) of$(0.5) million , or$(0.01) per basic and diluted share for Q3 2025.
- In Q3 2026, the Company recognized
$5.1 million in noncash income due to fair value adjustments related to warrant and contingent value rights (CVR) liability compared to$(5.5) million of noncash expense in Q3 2025.
- In Q3 2026, the Company recognized
- Cash Position: Cash, cash equivalents and investments were
$270.9 million as of September 30, 2026. Based on its current operating forecast, the Company believes available financial resources are sufficient to execute on its strategic priorities.
- Common and Fully Diluted Shares O/S: As of September 30, 2026, total shares of common stock outstanding were 59,439,959, and fully diluted common shares were 68,968,909, which included 6,999,571 shares issuable from outstanding awards under equity incentive plans, and 2,529,379 shares issuable upon exercise of warrants.
Conference Call Information
Zevra will host a conference call and audio webcast TODAY at 4:30 p.m. ET to discuss its corporate update and financial results for the third quarter 2026.
A link to the audio webcast is accessible on the “Events & Presentations” page in the Investor Relations section of the Zevra's website at investors.zevra.com. A replay of the webcast will be available for 90 days beginning at approximately 5:30 p.m. ET on November 3, 2026.
Additionally, interested participants and investors may access the conference call by dialing either:
- (800) 274-8461 (United States)
- +1 (203) 518-9814 (International)
- Conference ID: ZVRAQ326
About MIPLYFFA® (arimoclomol)
MIPLYFFA (arimoclomol) is Zevra’s approved therapy for the treatment of Niemann-Pick disease type C (NPC). Approved by the U.S. Food and Drug Administration on Sep. 20, 2024, MIPLYFFA (arimoclomol) increases the activation of the transcription factors EB (TFEB) and E3 (TFE3) resulting in the upregulation of coordinated lysosomal expression and regulation (CLEAR) genes. MIPLYFFA has also been shown to reduce unesterified cholesterol in the lysosomes of human NPC fibroblasts. The clinical significance of these findings is not fully understood. In the pivotal phase 3 trial, MIPLYFFA halted disease progression compared to placebo over the one-year duration of the trial when measured by the only validated disease progression measurement tool, the NPC Clinical Severity Scale. MIPLYFFA has also received Orphan Medicinal Product designation by the European Medicines Agency (EMA) for the treatment of NPC. The extensive data generated for MIPLYFFA has shown long-term, meaningful clinical outcomes with more than 5 years of patient experience across more than 270 NPC patients worldwide through a Phase 2/3 clinical trial, Open-Label Extension (OLE) study, Expanded Access Programs (EAP), and a pediatric sub-study, which is the most expansive clinical development program in NPC to date. Zevra has submitted a Marketing Authorization Application to the European Medicines Agency for the evaluation of arimoclomol for the treatment of Niemann-Pick disease type C.
INDICATIONS AND USAGE
MIPLYFFA is indicated for use in combination with miglustat for the treatment of neurological manifestations of Niemann-Pick disease type C (NPC) in adult and pediatric patients 2 years of age and older.
IMPORTANT SAFETY INFORMATION
Hypersensitivity Reactions: Hypersensitivity reactions such as urticaria and angioedema have been reported in patients treated with MIPLYFFA during Trial 1: two patients reported both urticaria and angioedema (
Embryofetal Toxicity: MIPLYFFA may cause embryofetal harm when administered during pregnancy based on findings from animal reproduction studies. Advise pregnant females of the potential risk to the fetus and consider pregnancy planning and prevention for females of reproductive potential.
Increased Creatinine without Affecting Glomerular Function: Across clinical trials of MIPLYFFA, mean increases in serum creatinine of
During MIPLYFFA treatment, use alternative measures that are not based on creatinine to assess renal function. Increases in creatinine reversed upon MIPLYFFA discontinuation.
The most common adverse reactions in Trial 1 (≥
Three (
To report SUSPECTED ADVERSE REACTIONS, contact Zevra Therapeutics, Inc. toll-free at 1-844-600-2237 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
Drug Interaction(s): Arimoclomol is an inhibitor of the organic cationic transporter 2 (OCT2) transporter and may increase the exposure of drugs that are OCT2 substrates. When MIPLYFFA is used concomitantly with OCT2 substrates, monitor for adverse reactions and reduce the dosage of the OCT2 substrate.
Use in Females and Males of Reproductive Potential: Based on animal findings, MIPLYFFA may impair fertility and may increase post-implantation loss and reduce maternal, placental, and fetal weights.
Renal Impairment: The recommended dosage of MIPLYFFA, in combination with miglustat, in patients with an eGFR ≥15 mL/minute to <50 mL/minute is lower than the recommended dosage (less frequent dosing) in patients with normal renal function.
MIPLYFFA capsules for oral use are available in the following strengths: 47 mg, 62 mg, 93 mg, and 124 mg.
For more information, please see the full Prescribing Information, including Instructions for Use.
About OLPRUVA®
OLPRUVA (sodium phenylbutyrate) is Zevra’s approved treatment for the treatment of certain UCDs. OLPRUVA (sodium phenylbutyrate) for oral suspension is a prescription medicine used along with certain therapies, including changes in diet, for the long-term management of adults and children weighing 44
Important Safety Information
Certain medicines may increase the level of ammonia in your blood or cause serious side effects when taken during treatment with OLPRUVA. Tell your doctor about all the medicines you or your child take, especially if you or your child take corticosteroids, valproic acid, haloperidol, and/or probenecid.
OLPRUVA can cause serious side effects, including: 1) nervous system problems (neurotoxicity). Symptoms include sleepiness, tiredness, lightheadedness, vomiting, nausea, headache, confusion, 2) low potassium levels in your blood (hypokalemia) and 3) conditions related to swelling (edema). OLPRUVA contains salt (sodium), which can cause swelling from salt and water retention. Tell your doctor right away if you or your child get any of these symptoms. Your doctor may do certain blood tests to check for side effects during treatment with OLPRUVA. If you have certain medical conditions such as heart, liver or kidney problems, are pregnant/planning to get pregnant or breast-feeding, your doctor will decide if OLPRUVA is right for you.
The most common side effects of OLPRUVA include absent or irregular menstrual periods, decreased appetite, body odor, bad taste or avoiding foods you ate prior to getting sick (taste aversion). These are not all of the possible side effects of OLPRUVA. Call your doctor for medical advice about side effects. You may report side effects to U.S. FDA at 1-800-FDA-1088.
About Celiprolol
Celiprolol is Zevra’s investigational clinical candidate for the treatment of Vascular Ehlers-Danlos Syndrome (VEDS). Celiprolol has been granted Orphan Drug and Breakthrough Therapy designations by the U.S. FDA. Zevra recently restarted enrollment in the DiSCOVER trial, a Phase 3 trial being conducted under a Special Protocol Assessment (SPA) agreement with the U.S. FDA. Celiprolol’s mechanism of action is designed to reduce the mechanical stress on collagen fibers within the arterial wall through vascular dilation and smooth muscle relaxation.
About Zevra Therapeutics, Inc.
Zevra Therapeutics, Inc. is a commercial-stage company with a late-stage pipeline committed to redefining what is possible in bringing life-changing therapies to people living with rare diseases. The Company is focused on broadening access through geographic expansion opportunities, progressing its pipeline toward key milestones, and delivering meaningful therapeutics. The commercialization of its lead product, marketed in the U.S. for Niemann-Pick disease type C (NPC), a rare, progressive neurodegenerative disease, provides a strong corporate foundation and validates its ability to advance therapies from development to market. Zevra's vision is realized through disciplined execution of its strategic plan and core values — patient centricity, integrity, accountability, innovation, and courage — which guide its efforts to deliver long-term value.
For more information, please visit www.zevra.com or follow us on X and LinkedIn.
Cautionary Note Concerning Forward-Looking Statements
This press release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include all statements that do not relate solely to historical or current facts, including without limitation statements regarding expanding access to MYPLYFFA, including with respect to the requested re-examination of the MAA for arimoclomol in the EU and the continued availability of our global EAP; the potential to accelerate development of the Company's treatment for Vascular Ehlers-Danlos Syndrome and a potential submission strategy; and the sufficiency of the Company’s available financial resources to execute on its strategic priorities. Forward-looking statements are based on information currently available to Zevra and its current plans or expectations. They are subject to several known and unknown uncertainties, risks, and other important factors that may cause our actual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. These and other important factors are described in detail in the “Risk Factors” section of Zevra’s Annual Report on Form 10-K for the year ended December 31, 2025, filed on March 9, 2026, and Zevra’s other filings with the Securities and Exchange Commission. While we may elect to update such forward-looking statements at some point in the future, except as required by law, we disclaim any obligation to do so, even if subsequent events cause our views to change. Although we believe the expectations reflected in such forward-looking statements are reasonable, we cannot assure that such expectations will prove correct. These forward-looking statements should not be relied upon as representing our views as of any date after the date of this press release.
Investor Contact
Nichol Ochsner
+1 (732) 754-2545
nochsner@zevra.com
Media Contact
Julie Downs
+1 (508) 246-3230
jdowns@zevra.com
| ZEVRA THERAPEUTICS, INC. UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (in thousands, except share and per share amounts) | ||||||||||||||||
| Three months ended September 30, | Nine months ended September 30, | |||||||||||||||
| 2026 | 2025 | 2026 | 2025 | |||||||||||||
| Revenue, net | $ | 37,756 | $ | 26,063 | $ | 113,639 | $ | 72,345 | ||||||||
| Cost of product revenue (excluding | (1,794 | ) | (1,238 | ) | (5,216 | ) | (14,962 | ) | ||||||||
| Intangible asset amortization | (315 | ) | (315 | ) | (947 | ) | (3,546 | ) | ||||||||
| Impairment of intangible assets | — | — | — | (58,710 | ) | |||||||||||
| Gain on sale of future royalties, intellectual property, and other assets, net | — | — | 43,314 | — | ||||||||||||
| Operating expenses: | ||||||||||||||||
| Research and development | (4,937 | ) | (3,432 | ) | (13,815 | ) | (10,123 | ) | ||||||||
| Selling, general and administrative | (19,130 | ) | (16,935 | ) | (56,472 | ) | (57,262 | ) | ||||||||
| Total operating expenses | (24,067 | ) | (20,367 | ) | (70,287 | ) | (67,385 | ) | ||||||||
| Income (loss) from operations | 11,580 | 4,143 | 80,503 | (72,258 | ) | |||||||||||
| Other income (expense): | ||||||||||||||||
| Gain on sale of PRV | — | — | — | 148,325 | ||||||||||||
| Loss on extinguishment of debt | — | — | (2,756 | ) | — | |||||||||||
| Loss on derivative liability | — | — | (7,216 | ) | — | |||||||||||
| Interest expense | — | (2,051 | ) | (1,711 | ) | (6,029 | ) | |||||||||
| Fair value adjustment related to warrant and CVR liability | 5,143 | (5,506 | ) | (297 | ) | (1,379 | ) | |||||||||
| Fair value adjustment related to investments | (39 | ) | 124 | (395 | ) | 119 | ||||||||||
| Interest and other income, net | 3,034 | 2,313 | 9,189 | 5,234 | ||||||||||||
| Total other income (expense) | 8,138 | (5,120 | ) | (3,186 | ) | 146,270 | ||||||||||
| Income (loss) before income taxes | 19,718 | (977 | ) | 77,317 | 74,012 | |||||||||||
| Income tax (expense) benefit | (510 | ) | 433 | (11,467 | ) | (2,948 | ) | |||||||||
| Net income (loss) | $ | 19,208 | $ | (544 | ) | $ | 65,850 | $ | 71,064 | |||||||
| Net income (loss) per share of common stock: | ||||||||||||||||
| Basic | $ | 0.31 | $ | (0.01 | ) | $ | 1.07 | $ | 1.20 | |||||||
| Diluted | $ | 0.26 | $ | (0.01 | ) | $ | 1.03 | $ | 1.16 | |||||||
| Weighted-average shares of common stock outstanding: | ||||||||||||||||
| Basic | 59,407,392 | 55,951,572 | 58,993,342 | 54,949,483 | ||||||||||||
| Diluted | 61,732,366 | 55,951,572 | 61,103,394 | 56,782,763 | ||||||||||||
| ZEVRA THERAPEUTICS, INC. UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS (in thousands, except share and par value amounts) | ||||||||
| September 30, 2026 | December 31, 2025 | |||||||
| Assets | ||||||||
| Current assets: | ||||||||
| Cash and cash equivalents | $ | 122,148 | $ | 62,406 | ||||
| Investments, current | 73,420 | 128,605 | ||||||
| Accounts and other receivables | 19,943 | 23,258 | ||||||
| Prepaid expenses and other current assets | 7,257 | 6,998 | ||||||
| Inventories, current | 3,070 | 1,740 | ||||||
| Total current assets | 225,838 | 223,007 | ||||||
| Investments, noncurrent | 75,323 | 47,879 | ||||||
| Inventories, noncurrent | — | 879 | ||||||
| Property and equipment, net | 816 | 489 | ||||||
| Operating lease right-of-use assets | 1,423 | 1,212 | ||||||
| Goodwill | 4,701 | 4,701 | ||||||
| Intangible assets, net | 5,474 | 6,421 | ||||||
| Other long-term assets | — | 143 | ||||||
| Total assets | $ | 313,575 | $ | 284,731 | ||||
| Liabilities and stockholders' equity | ||||||||
| Current liabilities: | ||||||||
| Accounts payable and accrued expenses | $ | 13,672 | $ | 11,598 | ||||
| Current portion of operating lease liabilities | 626 | 419 | ||||||
| Current portion of discount and rebate liabilities | 7,223 | 12,188 | ||||||
| Current portion of income tax payable | 18,532 | 13,710 | ||||||
| Other current liabilities | 1,316 | 1,362 | ||||||
| Total current liabilities | 41,369 | 39,277 | ||||||
| Long-term debt | — | 61,928 | ||||||
| Warrant liability | 7,712 | 9,575 | ||||||
| Income tax payable | 7,304 | 7,029 | ||||||
| Operating lease liabilities, less current portion | 602 | 859 | ||||||
| Discount and rebate liabilities, less current portion | 14,792 | 9,693 | ||||||
| Other long-term liabilities | 2,873 | 1,713 | ||||||
| Total liabilities | 74,652 | 130,074 | ||||||
| Commitments and contingencies | ||||||||
| Stockholders’ equity: | ||||||||
| Preferred stock: | ||||||||
| Undesignated preferred stock, | — | — | ||||||
| Common stock, | 6 | 6 | ||||||
| Additional paid-in capital | 609,618 | 588,458 | ||||||
| Treasury stock, at cost | (10,983 | ) | (10,983 | ) | ||||
| Accumulated deficit | (356,210 | ) | (422,060 | ) | ||||
| Accumulated other comprehensive loss | (3,508 | ) | (764 | ) | ||||
| Total stockholders' equity | 238,923 | 154,657 | ||||||
| Total liabilities and stockholders' equity | $ | 313,575 | $ | 284,731 | ||||
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What drove Zevra's third-quarter 2026 revenue?
Zevra's $37.8 million in Q3 2026 net revenue included $34.0 million from MIPLYFFA, $0.2 million from OLPRUVA and $3.6 million in net reimbursements from its global Expanded Access Program.
What contributed to Zevra's third-quarter 2026 profit?
Zevra reported $19.2 million in net income, including $5.1 million in noncash income from fair value adjustments to warrant and contingent value rights liabilities. Those adjustments produced $5.5 million in noncash expense in Q3 2025.
What regulatory discussions has Zevra held about celiprolol?
Zevra engaged with the FDA for a Type C meeting to discuss a potential submission strategy for celiprolol. Its event-driven Phase 3 DiSCOVER trial for vascular Ehlers-Danlos syndrome had 72 enrolled patients and four confirmed events.
How many patients were in Zevra's global Expanded Access Program?
Zevra's global Expanded Access Program had 134 patients enrolled as of September 30, 2026. The program provides arimoclomol to eligible patients.
What asset-sale gains affected Zevra's nine-month earnings comparison?
Zevra recorded a $43.314 million net gain on the sale of future royalties, intellectual property and other assets in the first nine months of 2026. The corresponding 2025 period included a $148.325 million gain on a priority review voucher sale and a $58.710 million intangible asset impairment.